Recently,Shenzhen NewDEL Biotech Co., Ltd. ("NewDEL Biotech"）announced the completion of tens of millions of RMB Series A financing. The investors in this round include existing shareholders and Cheng Capital. This continued investment not only recognizes the past performance of NewDEL Biotech but also anticipates its future development potential. The proceeds from this financing will be used to accelerate the domestic Phase I clinical trial of the innovative drug ND-003, the construction of the DEL+X technology platform (including DEL+AI, namely SMART DEL, DEL+protac, and DEL+molecular probes), as well as preclinical and early clinical development for other projects of the company.

NewDEL Biotech is the first biopharmaceutical enterprise incubated by the Guangdong Province Small Molecule Drug Innovation Center. It possesses a globally leading DEL (DNA-encoded library) live cell screening technology and continues to build the DEL+X technology platform, including SMART DEL, DEL+protac, and DEL+molecular probes. In its two-plus years since establishment, NewDEL Biotech has made remarkable progress in team building, technology platform construction, pipeline layout, and external collaborations. This progress includes the formation of a full industry chain team from the DEL technology center to the business marketing department for drug development, the establishment of the DEL+X technology platform and dozens of research and development pipelines, obtaining four dual-application clinical trial approvals from China and the United States, completing the first clinical dosing in early February, and securing cooperation orders worth tens of millions from listed pharmaceutical companies.

In 2023, the biopharmaceutical investment fervor took a steep downturn, with many investment institutions completely withdrawing from the biopharmaceutical arena. The entire new drug development field experienced a financing "rapid freeze." However, the success of this Series A financing once again demonstrates the capital market's recognition and trust in the research and development team and capabilities of NewDEL Biotech. This round of investment will further accelerate the pace of the company's research and clinical trials.

Regarding the completion of this round of financing, Mr. He Xun, Chairman of NewDEL Biotech, expressed his heartfelt gratitude to existing shareholders and Cheng Capital for their trust and support in NewDEL Biotech's innovative research and development capabilities, clinical development capabilities, and future commercialization potential. The funds from this financing will provide crucial support for further refining the company's technological platform, initiating clinical development of first-in-class innovative drugs and new pipeline projects, and driving progress forward.

Over the past year, despite enduring the capital winter, the company has relied on its solid technological reserves and R&D resources to address unmet clinical needs. It has constructed drug development pipelines and technological platforms with core competitiveness and differentiation. Remarkable achievements have been made in project advancement and external collaborations. The core team of NewDEL Biotech will adhere to a research and development strategy focused on cutting-edge innovation and differentiated positioning, dedicating themselves to diligent study, careful planning, and wholehearted effort to develop excellent drugs for patients, generate returns for investors, and seek development opportunities for the company.

To the managers of Hecheng Capital expresses great pleasure in having the opportunity to support the development of NewDEL Biotech through this round of investment. NewDEL Biotech, based on a profound understanding of small molecule drugs, has built an extremely competitive technological platform, focusing on unmet clinical needs and independently developing innovative drugs with international leading standards. In the face of challenges in the overall domestic innovative drug industry, NewDEL Biotech's innovation capabilities, efficient team execution, highly coordinated pipeline layout, and inspiring data have strongly demonstrated the company's value and development potential.Hecheng Capital is committed to assisting companies with global technological innovation in their growth. We have high expectations for the future research and development progress and clinical advancement of NewDEL Biotech, and we look forward to seeing NewDEL Biotech achieve even greater development after our investment.

About Hecheng Capital

Zhuhai Hecheng Zhiyi Capital Management Co., Ltd. (Hecheng Capital), established in 2015, is a professional investment management firm dedicated to long-term value investing. As a venture capital institution, the company adheres to the core values of "harmony breeds prosperity, integrity is fundamental," focusing on investing in and incubating innovative enterprises with "hardcore technology," as well as nurturing and empowering leading "node" enterprises. It has successfully invested in numerous high-tech enterprises in information technology, advanced manufacturing, new materials, and biopharmaceuticals.

About NewDEL Biotech

Shenzhen NewDEL Biotech Co., Ltd. ("NewDEL Biotech"）. was established in April 2021 and is an industrial company incubated and controlled by the Guangdong Innovation Center For Small Molecule Drug Discovery. Leveraging its independently developed "SmartDEL technology platform" and unique live cell screening technology, NewDEL Biotech focuses on addressing unmet clinical needs. It aims to establish an innovative drug lifecycle system dedicated to FIC (Focused Innovation Cluster) drug design, development, and industrialization. The company is committed to becoming a leading international biopharmaceutical company specializing in new drug research and development.

AboutSmall Molecule Center

Guangdong Innovation Center For Small Molecule Drug Discovery is a provincial-level manufacturing innovation center aimed at completing technology development and achieving initial commercial applications. Focused on the needs and common key technologies of biomedical innovation, it conducts independent research and parallel collaborative research to address industry bottlenecks. Additionally, it continuously explores sustainable development models that balance social and economic benefits. By co-building innovation consortia with industry entities, integrating capital, innovative carriers, and expert talents, it empowers industry upstream and downstream resources to promote high-quality industry development.